ClinicalTrials.gov
ClinicalTrials.gov Menu

Combined F-18 NaF and F-18 FDG PET/CT for Evaluation of Malignancy

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00725387
Recruitment Status : Suspended (Logistics)
First Posted : July 30, 2008
Last Update Posted : July 12, 2018
Sponsor:
Information provided by (Responsible Party):
Stanford University

Brief Summary:
Fluorine-18 Fluorodeoxyglucose (F-18 FDG) PET/CT is established as a powerful imaging tool for cancer detection and monitoring response to therapy. Sodium Fluorine-18 (F-18) was used in the 1970s for bone scanning and can be used as a skeletal tracer in current PET/CT scanners. The combined administration of F-18 and F-18 FDG in a single PET/CT scan for cancer detection was not attempted to date. We hope to learn what is the best approach for detection of cancer and thus to improve cancer treatment.

Condition or disease
Neoplasms

Study Type : Observational
Estimated Enrollment : 250 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: Combined F-18 NaF and F-18 FDG PET/CT for Evaluation of Malignancy
Study Start Date : August 2007
Estimated Primary Completion Date : December 2018
Estimated Study Completion Date : December 2018



Primary Outcome Measures :
  1. Percent of patients with evidence of new lesions on combined F-18/F-18 FDG PET/CT. [ Time Frame: not defined ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Patients must be referred for evaluation of bone metastases.
Criteria

Inclusion Criteria:

  • Patients older than 18-year-old, diagnosed with cancer
  • Patients must understand and voluntarily sign an Informed Consent form after the contents have been fully explained to them

Exclusion Criteria:

  • Patients who cannot complete a PET/CT scan
  • Pregnant women
  • Healthy volunteers
  • Patients participating in other research studies

The subjects will not be paid to participate in this protocol. No costs will be charged to the subjects.


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00725387


Locations
United States, California
Stanford University School of Medicine
Stanford, California, United States, 94305
Denmark
Aalborg Hospital
Aalborg, Denmark
India
Apollo Hospital
Chennai, India
Portugal
Coimbra University Hospital
Coimbra, Portugal
South Africa
Pretoria Academic Hospital
Pretoria, South Africa
Sponsors and Collaborators
Stanford University
Investigators
Principal Investigator: Andrei Iagaru M.D Stanford University

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Stanford University
ClinicalTrials.gov Identifier: NCT00725387     History of Changes
Other Study ID Numbers: VAR0024
98043 ( Other Identifier: Stanford University Alternate IRB Approval No. )
SU-07232008-1266 ( Other Identifier: Stanford University )
First Posted: July 30, 2008    Key Record Dates
Last Update Posted: July 12, 2018
Last Verified: July 2018